Group 1 - The economic development in Jurong is marked by significant project construction and high-quality development initiatives, with a focus on creating a strong industrial base [1] - Jiangsu Kaimi Membrane Equipment Technology Co., Ltd. is investing 1.5 billion yuan in its second phase, aiming to produce 200 sets of high-end separation membrane equipment annually, generating an additional 400 million yuan in sales [2] - Jiangsu Zhida High Voltage Electric Co., Ltd. is expanding its production capacity, with a projected doubling of output following the completion of its second phase project, which is set to be operational by October [2][3] Group 2 - Tiangong Technology Co., Ltd. is enhancing its manufacturing capabilities with the installation of advanced equipment to meet the growing demand for high-end titanium materials in various industries [3] - Jiangsu Youyuan New Materials Technology Co., Ltd. is preparing for the launch of its first production line, with expected annual output reaching 30 million yuan and plans for further expansion in the coming years [4] - The overall construction momentum in Jurong is strong, with 144 major projects underway and a planned investment of 12.205 billion yuan for the year, supported by improved business environments and expedited approval processes [5]

Core Viewpoint - Shenzhen Yahui Long Biotechnology Co., Ltd. plans to conduct foreign exchange hedging business with a maximum amount of RMB 600 million or equivalent foreign currency to mitigate exchange rate risks [2][3]. Group 1: Overview of Foreign Exchange Hedging Business - The purpose of the foreign exchange hedging business is to manage exchange rate and interest rate risks arising from the company's import and export operations, primarily involving foreign currency settlements [3]. - The hedging activities will be based on normal production and operations, aiming to avoid speculative and arbitrage trading [3][4]. Group 2: Transaction Amount and Funding - The company intends to use no more than RMB 600 million or equivalent foreign currency from its own funds for the hedging activities, with a maximum of RMB 30 million or equivalent foreign currency allocated for transaction margins and premiums [2][4]. - The funding will come from the company's own resources and will not involve raised funds [5]. Group 3: Transaction Methods and Approval - The hedging tools may include forward foreign exchange contracts, foreign exchange swaps, foreign exchange options, foreign exchange interest rate swaps, foreign exchange futures, and currency swaps [5]. - The board of directors approved the hedging proposal on January 15, 2026, and this matter does not require submission to the shareholders' meeting [8]. Group 4: Risk Analysis - The foreign exchange hedging business aims to effectively manage foreign currency assets and mitigate risks from exchange rate fluctuations, although it still carries certain risks such as market risk, credit risk, and liquidity risk [9][10]. - The company will not engage in speculative trading, focusing instead on risk management [11]. Group 5: Impact on the Company and Accounting Treatment - The foreign exchange hedging activities are intended to mitigate risks from exchange rate fluctuations, and related hedging instruments will be treated as trading financial assets/liabilities according to accounting standards [13].

天眼查显示，近日，莱阳市宝利生物科技有限责任公司成立，法定代表人为于明建，注册资本2000万人 民币，由新疆禾皇生物科技有限公司全资持股。 经营范围含技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；生物饲料研发；生物质 燃料加工；生物基材料制造；生物基材料销售；生物农药技术研发；生物基材料技术研发；发酵过程优 化技术研发；工业酶制剂研发；细胞技术研发和应用；化肥销售；复合微生物肥料研发。（除依法须经 批准的项目外，凭营业执照依法自主开展经营活动）许可项目：乳制品生产；食品销售。（依法须经批 准的项目，经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可证件为准） 序号股东名称持股比例1新疆禾皇生物科技有限公司100% 企业名称莱阳市宝利生物科技有限责任公司法定代表人于明建注册资本2000万人民币国标行业科学研究 和技术服务业>研究和试验发展>工程和技术研究和试验发展地址山东省烟台市莱阳市穴坊镇邵家村888 号0004-101办公楼企业类型有限责任公司(自然人投资或控股的法人独资)营业期限2026-1-15至无固定期 限登记机关莱阳市市场监督管理局 来源：市场资讯 ...

Core Viewpoint - The company, Aihuilong (688575), has announced plans to engage in foreign exchange hedging activities to mitigate currency risk, with a funding limit of up to 600 million RMB or equivalent foreign currency [1] Group 1: Stock Performance - As of January 16, 2026, Aihuilong's stock closed at 15.15 RMB, down 1.5% from the previous trading day [1] - The stock opened at 15.39 RMB, reached a high of 15.53 RMB, and a low of 15.00 RMB, with a trading volume of 1.15 billion RMB and a turnover rate of 1.33% [1] Group 2: Business Announcement - Aihuilong and its subsidiaries plan to conduct foreign exchange hedging with a maximum funding limit of 600 million RMB or equivalent foreign currency [1] - The expected maximum margin and premium for the transactions will be 30 million RMB or equivalent foreign currency, funded from the company's own resources [1] - The business will be valid for 12 months from the date of approval by the board of directors and the funds within the limit can be reused [1] - The board has approved this matter in its ninth meeting, and it does not require submission to the shareholders' meeting [1] - The purpose of this business is to avoid and prevent exchange rate risks, without engaging in speculation or arbitrage [1]

1月15日，"走进平谷.共创未来"首届韩国企业平谷行专场论坛和中韩企业冰雪联谊会活动在北京市平谷 区举办。活动通过"主题推介+企业分享+冰雪联谊"的形式，向韩国企业展示了平谷区在农业科技、现 代物流、休闲时尚等领域的发展成果与合作机会，推动双方合作从制造领域向食品健康、智慧物流、休 闲文旅等多元赛道深化延伸。 大韩贸易投资振兴公社(KOTRA)、斗山、希杰、圃美多、星宇车科技、大承株式会社等近三十家韩国 企业和商协会代表，与北京市、平谷区相关部门及企业共聚一堂，共谋发展。 活动现场，圃美多、大承株式会社、星宇车科技等已落地韩企代表分享了在平谷发展的真实感受，为潜 在投资者提供了可信参考；平谷区政府向为两地合作做出突出贡献的韩资企业代表颁发了"平谷国际友 好使者"聘书；与多家韩国企业在食品加工、新材料应用等领域签署了合作意向书。 论坛现场，韩国企业家们通过观看平谷区"农业高科技、物流大流量、休闲新时尚"的产业蓝图，深入了 解国家农业科技园区科研水平、发展前景和智慧农业场景，感受规模化物流产业集群和成熟的物流产业 生态。在"首届中韩企业冰雪联谊会"现场，嘉宾在银色山海徜徉，亲身体验时尚平谷的魅力。 活动围绕平谷区 ...

Core Insights - The Ministry of Industry and Information Technology has announced the first batch of "Biomanufacturing Pilot Capability Construction Platform List," with Huaxi Biological Technology (Tianjin) Co., Ltd. being awarded the highest "five-star" rating for its leading synthetic biology pilot platform [1][5] - Huaxi Biological is one of only five companies in the country to receive this top certification, highlighting its technological strength in the fields of cosmetics, food additives, and biopharmaceuticals [1][5] - The "five-star" certification brings attention to the critical infrastructure of pilot platforms in biomanufacturing, which is essential for bridging the gap between scientific research and industrial application [1][5] Industry Challenges and Solutions - The "valley of death" in biomanufacturing represents the significant challenge of transitioning research outcomes from the laboratory to market application, with China's technology transfer rate at only about 10% compared to 75% in developed countries [2][5] - Pilot testing is identified as a crucial step in overcoming this challenge, as it scales laboratory results from milligram to kilogram and ton levels, ensuring quality control, cost accounting, and safety verification [2][3] Huaxi Biological's Pilot Platform - Huaxi Biological has invested over 3 billion yuan to create the world's largest synthetic biology pilot transformation platform, covering 40,000 square meters and equipped with 64 pilot production lines [3][4] - The platform operates as a "biological foundry" and "debugging center," enabling year-round, green, and controllable industrial manufacturing by optimizing metabolic pathways through gene editing [3][4] - The intelligent central control system allows for real-time monitoring of thousands of indicators, enhancing predictability and control over complex biological processes [3][4] Flexibility and Cost Efficiency - The platform's modular and standardized design allows for rapid reconfiguration of production lines to meet diverse bioproduct testing needs, significantly improving equipment utilization and response speed [4] - A case study of Tianjin Zhonghe Gene Technology Co., Ltd. illustrates the platform's effectiveness, as it completed process scaling tests in one month at a 90% cost reduction compared to building its own pilot line [4] National Strategy and Industry Impact - The recognition of Huaxi Biological reflects the national strategy to develop biomanufacturing as a strategic emerging industry, with plans to cultivate over 20 pilot platforms by 2027 [5][6] - The global biomanufacturing market is projected to exceed $390 billion by 2030, positioning biomanufacturing as a key area of technological and industrial competition [5][6] - Huaxi Biological's platform serves as a public infrastructure for the industry, facilitating collaboration with universities, research institutions, and biotech startups, thus breaking down barriers between technology and industry [5][6]

Core Insights - Betaini Group has made significant progress in the upstream medical beauty industry chain with the approval of a new product by its strategic investment, Yizheng (Suzhou) Biotechnology Co., Ltd, which holds 15.73% of its shares [1][4] - The approved product, an injectable poly-L-lactic acid filler, is the first of its kind globally to be approved for use in the temporal region, marking a milestone for the company and the industry in China [1][4] Group 1 - The product received a Class III medical device registration certificate from the National Medical Products Administration (NMPA), indicating its compliance with regulatory standards [1] - The filler utilizes proprietary MEDBIOMA® poly-L-lactic acid material and EvolaONE® microsphere technology developed by the company's core team [1][4] Group 2 - Chengdu Yizhen, founded by a team of scientists led by Dr. Zhang Xiaojin, focuses on the clinical transformation of absorbable biomaterials and has previously launched other Class III medical devices [4] - The approval of this core product signifies a strategic move by Betaini to enhance its value chain in skin health through investment and collaboration in the upstream biomaterials sector [4]

科创医药ETF（588860）成立日期2024年8月8日，最新规模2.06亿。今年以来收益9.96%，同类排名 1057/5531；近一年收益42.75%，同类排名1798/4215；成立以来收益52.78%。 科创医药ETF（588860）基金经理为史宝珖。 截至发稿，史宝珖累计任职时间4年48天，现任基金资产总规模38.16亿元，任职期间最佳基金回报 96.85%， 任职期间最差基金回报-31.39%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 1月16日，华大智造跌5.12%，截至发稿，报68.32元/股，成交2.74亿元，换手率0.95%，总市值284.56亿 元。华大智造股价已经连续3天下跌，区间累计跌幅8.59%。 资料显示，深圳华大智造科技股份有限公司位于广东省深圳市盐田区北山工业区综合楼及11栋2楼，成 立日期2016年4月13日，上市日期2022年9月9日，公司主营业务涉及专注于生命科学与生物技术领域,以 仪器设备、试剂耗材等相 ...

□四川日报全媒体记者 肖莹佩 去年我来成都出差超过40次。"1月14日，在2026成都高新区产业·资本对接会上，广东汉邦激光科 技有限公司董事长刘建业用这句话，为项目路演结尾。 如今，产业基金已成为地方推动产业升级、培育新动能的重要工具。对接会现场发布的产业融资 需求清单和产业基金投向清单，更成为逾400名与会人士关注的焦点。从项目路演看赋能 "基金招商"促进产业延链补链强链 通过"基金招商"促进产业延链补链强链，是政府产业基金的作用之一。对高科技企业而言，也是 发展助推器。 同为路演企业，上海星思半导体股份有限公司过去几年通过自主创新，在5G和卫星通信两大产品 线上取得重大突破。2025年6月，该公司完成B+轮融资，投资方包括成都高新区重点搭建的产业 投资平台策源资本等。在资金支持下，星思半导体产业化步伐进一步加快，预计下周，其位于成 都未来科技城的新产线就将开工。"新一轮融资主要用于制造生产。"星思半导体融资总经理艾孜 买提说。 当天，还有成都越凡创新科技有限公司、四川至善唯新生物科技有限公司等本土培育的优质企业 登场，围绕商用移动机器人、rAAV基因治疗等领域展开推介。凭借硬核技术与清晰的产业化路 径， ...

从行业来看，上述榜单中企业数量最多的前五大行业分别是半导体、工业设备、生物科技、新能源和软 件服务行业，分别有104家、96家、68家、59家、38家，总计占比46%。 值得注意的是，上述榜单的统计截止日期为2025年5月。自该时间节点至今，已有为数不少的独角兽企 业成功上市，相关企业未纳入本次榜单统计范围。 （文章来源：中国经营报） 1月15日，胡润研究院于北京亦庄发布《2025胡润中国独角兽毕业榜》，该榜单列出了中国成立于2000 年之后、价值10亿美元以上的上市公司，共796家。 据悉，这是胡润研究院首次发布相关榜单。上述榜单显示，北京、上海两地相关上市公司均已超百家， 分别为101家、113家。同时，榜单前十名企业中，有4家总部位于北京，3家总部位于上海。 ...